176 related articles for article (PubMed ID: 29906649)
1. Identification of new drug-like compounds from millets as Xanthine oxidoreductase inhibitors for treatment of Hyperuricemia: A molecular docking and simulation study.
Pathak RK; Gupta A; Shukla R; Baunthiyal M
Comput Biol Chem; 2018 Oct; 76():32-41. PubMed ID: 29906649
[TBL] [Abstract][Full Text] [Related]
2. [Inhibitors of xanthine oxidoreductase].
Okamoto K
Nihon Rinsho; 2008 Apr; 66(4):748-53. PubMed ID: 18409526
[TBL] [Abstract][Full Text] [Related]
3. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Chen C; Lü JM; Yao Q
Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
[TBL] [Abstract][Full Text] [Related]
4. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
5. Exploring Asphodelus microcarpus as a source of xanthine oxidase inhibitors: Insights from in silico and in vitro studies.
Di Petrillo A; Siguri C; Delogu GL; Fais A; Era B; Floris S; Pintus F; Kumar A; Fantini MC; Olla S
Chem Biol Interact; 2024 Jul; 397():111087. PubMed ID: 38823536
[TBL] [Abstract][Full Text] [Related]
6. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.
Okamoto K; Nishino T
J Nippon Med Sch; 2008 Feb; 75(1):2-3. PubMed ID: 18360072
[TBL] [Abstract][Full Text] [Related]
7. Effect of luteolin on xanthine oxidase: inhibition kinetics and interaction mechanism merging with docking simulation.
Yan J; Zhang G; Hu Y; Ma Y
Food Chem; 2013 Dec; 141(4):3766-73. PubMed ID: 23993547
[TBL] [Abstract][Full Text] [Related]
8. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
9. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
Takano Y; Hase-Aoki K; Horiuchi H; Zhao L; Kasahara Y; Kondo S; Becker MA
Life Sci; 2005 Mar; 76(16):1835-47. PubMed ID: 15698861
[TBL] [Abstract][Full Text] [Related]
10. Xanthine oxidoreductase and its inhibitors: relevance for gout.
Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
[TBL] [Abstract][Full Text] [Related]
11. Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity.
Šmelcerović A; Tomović K; Šmelcerović Ž; Petronijević Ž; Kocić G; Tomašič T; Jakopin Ž; Anderluh M
Eur J Med Chem; 2017 Jul; 135():491-516. PubMed ID: 28478180
[TBL] [Abstract][Full Text] [Related]
12. Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity.
Niu Y; Li H; Gao L; Lin H; Kung H; Lin MC; Leung KS; Wong MH; Xiong W; Li L
J Pharmacol Sci; 2017 Nov; 135(3):114-120. PubMed ID: 29132796
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Renoprotective Effect of Febuxostat for the Treatment of Hyperuricemia between Patients with and without Type 2 Diabetes Mellitus: A Retrospective Observational Study.
Ito H; Antoku S; Abe M; Omoto T; Shinozaki M; Nishio S; Mifune M; Togane M; Nakata M; Yamashita T
Intern Med; 2016; 55(22):3247-3256. PubMed ID: 27853065
[TBL] [Abstract][Full Text] [Related]
14. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2.
Nakamura M; Fujita K; Toyoda Y; Takada T; Hasegawa H; Ichida K
Drug Metab Pharmacokinet; 2018 Feb; 33(1):77-81. PubMed ID: 29342419
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and bioevaluation of 1-phenyl-pyrazole-4-carboxylic acid derivatives as potent xanthine oxidoreductase inhibitors.
Li J; Wu F; Liu X; Zou Y; Chen H; Li Z; Zhang L
Eur J Med Chem; 2017 Nov; 140():20-30. PubMed ID: 28918097
[TBL] [Abstract][Full Text] [Related]
17. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
18. Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice.
Meng X; Mao Z; Li X; Zhong D; Li M; Jia Y; Wei J; Yang B; Zhou H
Oncotarget; 2017 Jun; 8(25):40305-40317. PubMed ID: 28445133
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia.
Komoriya K; Hoshide S; Takeda K; Kobayashi H; Kubo J; Tsuchimoto M; Nakachi T; Yamanaka H; Kamatani N
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1119-22. PubMed ID: 15571213
[TBL] [Abstract][Full Text] [Related]
20. Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.
Terawaki H; Hoshi H; Kazama JJ
Clin Exp Nephrol; 2017 Apr; 21(2):356-357. PubMed ID: 28247173
[No Abstract] [Full Text] [Related]
[Next] [New Search]
